Key Points
- Xeris Biopharma insider Beth Hecht sold 16,667 shares on June 1 at an average price of $6.06, totaling about $101,002. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- After the transaction, Hecht still directly owned 1,176,506 shares valued at roughly $7.13 million, and the sale represented a 1.40% decrease in her ownership. She also sold similar-sized blocks in April and May.
- XERS shares were down 1.2% and the company recently reported quarterly EPS of $0.01 on revenue of $83.13 million, beating revenue estimates. Analysts currently have a Hold consensus rating with an average price target of $10.80.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the firm's stock in a transaction on Monday, June 1st. The shares were sold at an average price of $6.06, for a total transaction of $101,002.02. Following the completion of the transaction, the insider directly owned 1,176,506 shares of the company's stock, valued at approximately $7,129,626.36. This trade represents a 1.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Beth Hecht also recently made the following trade(s):
- On Friday, May 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $6.23, for a total transaction of $103,835.41.
- On Wednesday, April 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $5.99, for a total transaction of $99,835.33.
Xeris Biopharma Trading Down 1.2%
XERS stock opened at $6.00 on Wednesday. The firm has a fifty day moving average price of $6.05 and a 200 day moving average price of $6.62. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $4.30 and a fifty-two week high of $10.08. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.50 and a current ratio of 2.12. The firm has a market cap of $1.04 billion, a PE ratio of 100.00 and a beta of 0.78.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. The firm had revenue of $83.13 million during the quarter, compared to analyst estimates of $79.83 million. Sell-side analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. Kestra Advisory Services LLC purchased a new position in Xeris Biopharma during the fourth quarter worth $25,000. KBC Group NV purchased a new position in Xeris Biopharma during the first quarter worth $27,000. AlphaQuest LLC bought a new stake in shares of Xeris Biopharma during the third quarter worth $35,000. Caitong International Asset Management Co. Ltd lifted its position in shares of Xeris Biopharma by 9,276.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company's stock worth $59,000 after purchasing an additional 7,421 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Xeris Biopharma by 29.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company's stock worth $63,000 after purchasing an additional 1,820 shares during the last quarter. 42.75% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on the stock. Weiss Ratings lowered shares of Xeris Biopharma from a "hold (c-)" rating to a "sell (d+)" rating in a report on Monday, May 11th. Wall Street Zen raised shares of Xeris Biopharma from a "buy" rating to a "strong-buy" rating in a research note on Saturday, March 7th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Xeris Biopharma in a research note on Monday, March 2nd. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Xeris Biopharma has a consensus rating of "Hold" and an average price target of $10.80.
Get Our Latest Report on Xeris Biopharma
Xeris Biopharma Company Profile
(
Get Free Report)
Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company's proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.
The company's flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
